Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Possible New Histological Prognostic Index for Large B-Cell Lymphoma

Hideaki Nitta
,
Haruko Takizawa
,
Toru Mitsumori
,
Hiroko Iizuka-Honma
,
Yoshihiko Araki
ORCID logo ,
Maki Fujishiro
,
Shigeki Tomita
,
Satsuki Kishikawa
,
Akane Hashizume
,
Tomohiro Sawada
,
Mitsuo Okubo
,
Yasunobu Sekiguchi
,
Miki Ando
,
Masaaki Noguchi
*
Version 1 : Received: 18 August 2023 / Approved: 18 August 2023 / Online: 18 August 2023 (11:42:22 CEST)

A peer-reviewed article of this Preprint also exists.

Nitta, H.; Takizawa, H.; Mitsumori, T.; Iizuka-Honma, H.; Araki, Y.; Fujishiro, M.; Tomita, S.; Kishikawa, S.; Hashizume, A.; Sawada, T.; Okubo, M.; Sekiguchi, Y.; Ando, M.; Noguchi, M. Possible New Histological Prognostic Index for Large B-Cell Lymphoma. J. Clin. Med. 2023, 12, 6324. Nitta, H.; Takizawa, H.; Mitsumori, T.; Iizuka-Honma, H.; Araki, Y.; Fujishiro, M.; Tomita, S.; Kishikawa, S.; Hashizume, A.; Sawada, T.; Okubo, M.; Sekiguchi, Y.; Ando, M.; Noguchi, M. Possible New Histological Prognostic Index for Large B-Cell Lymphoma. J. Clin. Med. 2023, 12, 6324.

Abstract

We conducted a retrospective analysis of the immunohistochemical (IHC) staining GRP94, an ER stress protein on large B-cell lymphoma (LBCL) cells, intracellular p53, and 15 factors involved in the metabolism of CHOP regimen :AKR1C3 (HO-metabolism), CYP3A4 (CHOP-metabolism) and HO efflux pumps (MDR1, MRP1). The study subjects were 42 patients with LBCL at our hospital. IHC staining using antibodies against the 17 factors. The odds ratios by logistic regression analysis using a dichotomous variable of CR, non-CR/relapse were statistically significant: for MDR1, MRP1, and AKR1C3. The overall survival (OS) after R-CHOP was compared by the log-rank test. The four groups showed that Very good (5-year OS, 100%) consisted of 4 patients showed negative IHC staining for both GRP94 and CYP3A4. Very poor (1-year OS, 0%), consisted of 3 patients who showed positive results of IHC for both GRP94 and CYP3A4. The remaining 35 patients comprised two subgroups: Good (5-year OS 60-80%.): 15 patients who showed negative staining for both MDR1 and AKR1C3, Poor: 5-year OS, 10-20%) :20 patients who showed positive staining for either MDR, AKR1C3,,MRP1 or p53. The Histological Prognostic Index (HPI) (The four groups: Very poor, Poor, Good, and Very pood) is a breakthrough method for stratifying patients based on factors involved in the development of treatment resistance.

Keywords

Large B-cell lymphoma (LBCL); Immunohistochemical (IHC) staining; Glucoseregulated protein 94 (GRP94); CYP3A4; Multidrug resistance protein 1 (MDR1); Aldo-keto reductase family 1 member C3 (AKR1C3); Multi-drug resistance-associated protein 1 (MRP1); P53

Subject

Medicine and Pharmacology, Hematology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.